{"id":1006398,"date":"2026-09-28T16:11:47","date_gmt":"2026-09-28T20:11:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\/"},"modified":"2026-09-28T16:11:47","modified_gmt":"2026-09-28T20:11:47","slug":"attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\/","title":{"rendered":"Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SAN CARLOS, Calif., Sept.  28, 2026  (GLOBE NEWSWIRE) &#8212; Attovia Therapeutics, Inc. (\u201cAttovia\u201d) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that it will present new clinical, translational, and preclinical data across its pipeline at the European Academy of Dermatology and Venereology (EADV) Congress 2026 and the Fall Clinical Dermatology Conference (FCD) 2026.<\/p>\n<p>Attovia will present four posters: three on ATTO-1310, a next generation anti-IL-31 ATTOBODY-based therapeutic, and one on ATTO-2306, a novel long-acting anti-IL-31 and IL-13 bispecific. The ATTO-1310 posters will highlight Phase 1a data in healthy volunteers, translational data advancing the understanding of IL-31 across pruritic skin diseases, and interim Phase 1b data in patients with high-itch atopic dermatitis (AD) or with chronic pruritus. The ATTO-2306 poster will feature new preclinical data.<\/p>\n<p>The EADV Congress 2026 will take place September 30 &#8211; October 3, 2026 in Vienna, Austria and FCD 2026 will take place on October 8-11, 2026 in Las Vegas, Nevada. Presentation details are below.<\/p>\n<p>\n        <strong><br \/>\n          <u>ATTO-1310<\/u><br \/>\n        <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">EADV 2026 Poster Presentations\n<ul type=\"circle\">\n<li style=\"margin-bottom:8pt\"><strong>Title: <\/strong>Safety, Pharmacokinetics, and Pharmacodynamics of ATTO-1310, a Novel Anti-IL-31 ATTOBODY-Fc Fusion Protein, in Healthy Adults (Abstract: AS-1248)<\/li>\n<li style=\"margin-bottom:8pt\"><strong>Title:<\/strong> Ultra-Sensitive Detection of Circulating IL-31 Reveals Elevated Levels Across Pruritic Skin Diseases (Abstract: AS-3150)<\/li>\n<\/ul>\n<\/li>\n<li style=\"margin-bottom:8pt\">FCD 2026 Poster Presentation\n<ul type=\"circle\">\n<li style=\"margin-bottom:8pt\"><strong>Title:<\/strong> Efficacy and Safety of a Single Dose of ATTO-1310, a Novel Anti-IL-31 ATTOBODY-Fc Fusion Protein: Interim Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients with Atopic Dermatitis or with Chronic Pruritus\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\n        <strong><br \/>\n          <u>ATTO-2306<\/u><br \/>\n        <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">FCD 2026 Poster Presentation\n<ul type=\"circle\">\n<li style=\"margin-bottom:8pt\"><strong>Title:<\/strong> Preclinical Characterization of ATTO-2306, a Long-Acting Bispecific Antibody Targeting IL-13 and IL-31 for Type 2 Inflammatory Skin Diseases\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p align=\"justify\">Following each congress, the posters will be available on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3jskpgI2cv9gje_UkcWx72zpsC2qwZLnP3gEaL_WS49SBIFkjpuaxFpG5y8fq1q08G9hBDFFsr1phBE0afiws3fhacWVe7gocb7Zgk6M-LV4EBpGGBRoXyteQopkIvDa\" rel=\"nofollow\" target=\"_blank\">Publications page<\/a> of the Attovia website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oFf3nCEI0V4V7lZ0v4Y07h4R9ZmGAktxT-q-7uqUGx-k9PryTpMBLk-Y-w_0WnK1ecdtX_HyqVh1Fcl29aCpr2CLbQSA0IT84o6dsW3Fq7o=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.attovia.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Attovia Therapeutics, Inc.<\/strong><br \/>\n        <br \/>Attovia\u2122 is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. All of its product candidates have been internally discovered using its ATTOBODY\u2122 biparatopic biologics platform. Attovia\u2019s ATTOBODY platform uses an evolution-driven, high-throughput process that allows for rapid discovery and creation of a high diversity of potential product candidates.<\/p>\n<p align=\"justify\">Attovia\u2019s lead programs include ATTO-1310, an anti-IL-31 ATTOBODY-based therapeutic in clinical development for chronic pruritic diseases; ATTO-2306, a long-acting bispecific antibody targeting IL-31 and IL-13 in IND-enabling studies for atopic dermatitis and other immune-mediated skin diseases; and ATTO-1091, a trispecific antibody targeting TL1A, IL-23p19, and integrin \u03b14\u03b27 in IND-enabling studies for inflammatory bowel disease. Attovia\u2019s other programs include highly innovative conditional \u2018AND\u2019 gated bispecific immune cell survival blockers and multispecifics.<\/p>\n<p align=\"justify\">\n        <strong>Investor and Media Contact<\/strong>\n      <\/p>\n<p align=\"justify\">Attovia Therapeutics<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Kh5DwtxGyemluAFUk4g5XpBdE4O--N5pDy0GkQKB9ILiPVDE--YWtyGgmzOaDDMbGRcIGAjYSh11rZusFdiWiw==\" rel=\"nofollow\" target=\"_blank\">ir@attovia.com<\/a><\/p>\n<p align=\"justify\">PJ Kelleher<br \/>LifeSci Advisors LLC<br \/>617-430-7579<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uicvv_JS0IPx-6VPqFtqXU7tZPtehIjUz4_738WSCN1aqKbipCOXX7kWuPNvFOVIUKW1YMUaJmr8ypdeRa_K_dc4_oh4gtQY9vYGoS3RAuHOHWqBZPmn32tnjZNwwy39\" rel=\"nofollow\" target=\"_blank\">pkelleher@lifesciadvisors.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTE5NSM3ODY2OTA1IzIyNjA0NTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NWVmZTdjOTgtMDg1OS00NzJjLTkyOGYtZjMxYzlmOTc2MWM4LTEyNzIwMDEtMjAyNi0wOS0yOC1lbg==\/tiny\/Attovia-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN CARLOS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) &#8212; Attovia Therapeutics, Inc. (\u201cAttovia\u201d) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that it will present new clinical, translational, and preclinical data across its pipeline at the European Academy of Dermatology and Venereology (EADV) Congress 2026 and the Fall Clinical Dermatology Conference (FCD) 2026. Attovia will present four posters: three on ATTO-1310, a next generation anti-IL-31 ATTOBODY-based therapeutic, and one on ATTO-2306, a novel long-acting anti-IL-31 and IL-13 bispecific. The ATTO-1310 posters will highlight Phase 1a data in healthy volunteers, translational data advancing the understanding of IL-31 across pruritic skin diseases, and interim Phase 1b data in patients with high-itch atopic &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1006398","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN CARLOS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) &#8212; Attovia Therapeutics, Inc. (\u201cAttovia\u201d) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that it will present new clinical, translational, and preclinical data across its pipeline at the European Academy of Dermatology and Venereology (EADV) Congress 2026 and the Fall Clinical Dermatology Conference (FCD) 2026. Attovia will present four posters: three on ATTO-1310, a next generation anti-IL-31 ATTOBODY-based therapeutic, and one on ATTO-2306, a novel long-acting anti-IL-31 and IL-13 bispecific. The ATTO-1310 posters will highlight Phase 1a data in healthy volunteers, translational data advancing the understanding of IL-31 across pruritic skin diseases, and interim Phase 1b data in patients with high-itch atopic &hellip; Continue reading &quot;Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-28T20:11:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTE5NSM3ODY2OTA1IzIyNjA0NTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026\",\"datePublished\":\"2026-09-28T20:11:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\\\/\"},\"wordCount\":443,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNTE5NSM3ODY2OTA1IzIyNjA0NTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\\\/\",\"name\":\"Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNTE5NSM3ODY2OTA1IzIyNjA0NTE=\",\"datePublished\":\"2026-09-28T20:11:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNTE5NSM3ODY2OTA1IzIyNjA0NTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNTE5NSM3ODY2OTA1IzIyNjA0NTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\/","og_locale":"en_US","og_type":"article","og_title":"Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026 - Market Newsdesk","og_description":"SAN CARLOS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) &#8212; Attovia Therapeutics, Inc. (\u201cAttovia\u201d) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that it will present new clinical, translational, and preclinical data across its pipeline at the European Academy of Dermatology and Venereology (EADV) Congress 2026 and the Fall Clinical Dermatology Conference (FCD) 2026. Attovia will present four posters: three on ATTO-1310, a next generation anti-IL-31 ATTOBODY-based therapeutic, and one on ATTO-2306, a novel long-acting anti-IL-31 and IL-13 bispecific. The ATTO-1310 posters will highlight Phase 1a data in healthy volunteers, translational data advancing the understanding of IL-31 across pruritic skin diseases, and interim Phase 1b data in patients with high-itch atopic &hellip; Continue reading \"Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-28T20:11:47+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTE5NSM3ODY2OTA1IzIyNjA0NTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026","datePublished":"2026-09-28T20:11:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\/"},"wordCount":443,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTE5NSM3ODY2OTA1IzIyNjA0NTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\/","name":"Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTE5NSM3ODY2OTA1IzIyNjA0NTE=","datePublished":"2026-09-28T20:11:47+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTE5NSM3ODY2OTA1IzIyNjA0NTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNTE5NSM3ODY2OTA1IzIyNjA0NTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/attovia-therapeutics-to-present-new-data-on-atto-1310-and-atto-2306-at-eadv-2026-and-fall-clinical-dermatology-conference-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006398","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1006398"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006398\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1006398"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1006398"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1006398"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}